OptiMAL® R&D Update

AI SummaryClose X

Fusion Antibodies plc announced an update on its OptiMAL® R&D project, revealing successful validation for isolating specific antibodies against both proteins and smaller peptide targets. This expands the potential market reach and revenue opportunities for OptiMAL®. The company had previously demonstrated single-digit nM affinities for antibodies against protein targets. The next step involves testing the antibodies in cell-based assays at the National Cancer Institute (NCI) to assess their potential as therapeutic drug candidates. Fusion Antibodies remains on track for the commercial launch of OptiMAL® in December 2025. The NCI has requested an extension of the agreement to use the OptiMAL® platform for additional targets in the coming years, and negotiations are underway to establish mutually agreeable terms.

Disclaimer*

UK 100

Latest directors dealings